Skip to main content
Top
Published in: Journal of Anesthesia 5/2018

01-10-2018 | Original Article

In vitro changes in the proportion of protein-unbound-free propofol induced by valproate

Authors: Minako Ishii-Maruhama, Hitoshi Higuchi, Mai Nakanou, Yuka Honda-Wakasugi, Akiko Yabuki-Kawase, Shigeru Maeda, Takuya Miyawaki

Published in: Journal of Anesthesia | Issue 5/2018

Login to get access

Abstract

Purpose

It has been reported that oral valproate (VPA) reduces the dose of propofol required for sedation. As  a potential reason for this, it is considered that VPA displaces serum protein-bound propofol and increases the proportion of protein-unbound-free propofol. To examine this hypothesis, the present in vitro study investigated the influence of VPA on the proportion of protein-unbound-free propofol in human serum samples.

Methods

Serum samples were collected from 10 healthy volunteers, who were not taking any medication. VPA (final concentration: 0.05, 0.1 or 1 mg/mL) and propofol (final concentration: 1 or 5 µg/mL) were mixed with serum samples with normal (4.0 g/dL) or low (2.5 g/dL) albumin concentrations. Then, protein-unbound-free propofol was extracted from the samples, and its concentration was measured using high-performance liquid chromatography. We compared the proportion of protein-unbound-free propofol in each of the VPA-containing samples with that in serum samples without VPA (control).

Results

In the serum samples with normal albumin concentrations, 1 mg/mL VPA significantly increased the proportion of protein-unbound-free propofol at 1 and 5 µg/mL propofol. Furthermore, in the serum samples with low albumin concentrations, the proportion of protein-unbound-free propofol was significantly increased by both 0.1 and 1 mg/mL VPA at propofol concentrations of 1 and 5 µg/mL.

Conclusion

VPA might increase the proportion of protein-unbound-free propofol in human serum via displacement reactions.
Literature
1.
go back to reference van Blarikom W, Tan IY, Aldenkamp AP, van Gennep AT. Epilepsy, intellectual disability, and living environment: a critical review. Epilepsy Behav. 2006;9:14–8.CrossRef van Blarikom W, Tan IY, Aldenkamp AP, van Gennep AT. Epilepsy, intellectual disability, and living environment: a critical review. Epilepsy Behav. 2006;9:14–8.CrossRef
2.
go back to reference Perucca E. Pharmacologocal and therapeutic properties of valproate. A summary after 35 years of clinical experiences. CNS Drugs. 2002;16:695–714.CrossRef Perucca E. Pharmacologocal and therapeutic properties of valproate. A summary after 35 years of clinical experiences. CNS Drugs. 2002;16:695–714.CrossRef
3.
go back to reference Ishii M, Higuchi H, Maeda S, Tomoyasu Y, Egusa M, Miyawaki T. The influence of oral VPA on the required dose of propofol for sedation during dental treatment in patients with mental retardation: a prospective observer-binded cohort study. Epilepsia. 2012;53:e13–6.CrossRef Ishii M, Higuchi H, Maeda S, Tomoyasu Y, Egusa M, Miyawaki T. The influence of oral VPA on the required dose of propofol for sedation during dental treatment in patients with mental retardation: a prospective observer-binded cohort study. Epilepsia. 2012;53:e13–6.CrossRef
4.
go back to reference Hızlı Sayar G, Eryılmaz G, Semieoğlu S, Ozten E, Göğcegöz Gül I. Influence of valproate on the required dose of propofol for anesthesia during electroconvulsive therapy of bipolar affective disorder patients. Neuropsychiatr Dis Treat. 2014;10:433–8.CrossRef Hızlı Sayar G, Eryılmaz G, Semieoğlu S, Ozten E, Göğcegöz Gül I. Influence of valproate on the required dose of propofol for anesthesia during electroconvulsive therapy of bipolar affective disorder patients. Neuropsychiatr Dis Treat. 2014;10:433–8.CrossRef
5.
go back to reference Wen X, Wang JS, Kivistö KT, Neuvonen PJ, Backman JT. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol. 2001;52:547–53.CrossRef Wen X, Wang JS, Kivistö KT, Neuvonen PJ, Backman JT. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol. 2001;52:547–53.CrossRef
6.
go back to reference Ethell BT, Anderson GD, Burchell B. The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases. Biochem Pharmacol. 2003;65:1441–9.CrossRef Ethell BT, Anderson GD, Burchell B. The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases. Biochem Pharmacol. 2003;65:1441–9.CrossRef
7.
go back to reference Hiraoka H, Yamamoto K, Miyoshi S, Morita T, Nakamura K, Kadoi Y, Kunimoto F, Horiuchi R. Kidneys contribute to the extrahepatic clearance of propofol in humans, but not lungs and brain. Br J Clin Pharmacol. 2005;60(2):176–82.CrossRef Hiraoka H, Yamamoto K, Miyoshi S, Morita T, Nakamura K, Kadoi Y, Kunimoto F, Horiuchi R. Kidneys contribute to the extrahepatic clearance of propofol in humans, but not lungs and brain. Br J Clin Pharmacol. 2005;60(2):176–82.CrossRef
8.
go back to reference Johannessen CU, Johannessen SI. Valproate: past, present, and future. CNS Drug Rev. 2003;9(2):199–216.CrossRef Johannessen CU, Johannessen SI. Valproate: past, present, and future. CNS Drug Rev. 2003;9(2):199–216.CrossRef
9.
go back to reference Gin T. Pharmacodynamics of propofol and free drug concentrations. Anesthesiology. 1993;78(3):604–5.CrossRef Gin T. Pharmacodynamics of propofol and free drug concentrations. Anesthesiology. 1993;78(3):604–5.CrossRef
10.
go back to reference Ohmori J, Maeda S, Higuchi H, Ishii M, Arai Y, Tomoyasu Y, Kohjitani A, Shimada M, Miyawaki T. Propofol increases the rate of albumin-unbound-free midazolam in serum albumin solution. J Anesth. 2011;25:618–20.CrossRef Ohmori J, Maeda S, Higuchi H, Ishii M, Arai Y, Tomoyasu Y, Kohjitani A, Shimada M, Miyawaki T. Propofol increases the rate of albumin-unbound-free midazolam in serum albumin solution. J Anesth. 2011;25:618–20.CrossRef
11.
go back to reference Dawidowicz AL, Kalitynski R, Kobielski M, Pieniadz J. Influence of propofol concentration in human plasma on free fraction of the drug. Chem Biol Interact. 2006;159(2):149–55.CrossRef Dawidowicz AL, Kalitynski R, Kobielski M, Pieniadz J. Influence of propofol concentration in human plasma on free fraction of the drug. Chem Biol Interact. 2006;159(2):149–55.CrossRef
12.
go back to reference Mather LE, Selby DG, Runciman WB, McLean CF. Propofol: Assay and regional mass balance in the sheep. Xenobiotica. 1989;19(11):1337–47.CrossRef Mather LE, Selby DG, Runciman WB, McLean CF. Propofol: Assay and regional mass balance in the sheep. Xenobiotica. 1989;19(11):1337–47.CrossRef
13.
go back to reference MacKichan JJ. Protein binding during drug displacement interactions fact or fiction? Clin Pharmacokinet. 1989;16:65–73.CrossRef MacKichan JJ. Protein binding during drug displacement interactions fact or fiction? Clin Pharmacokinet. 1989;16:65–73.CrossRef
14.
go back to reference Gin T, Yau G, Jong W, Tan P, Leung RK, Chan K. Disposition of propofol at caesarean section and in the postpartum period. Br J Anaesth. 1991;67(1):49–53.CrossRef Gin T, Yau G, Jong W, Tan P, Leung RK, Chan K. Disposition of propofol at caesarean section and in the postpartum period. Br J Anaesth. 1991;67(1):49–53.CrossRef
15.
go back to reference Leslie K, Crankshaw DP. Potency of propofol for loss of consciousness after a single dose. Br J Anaesth. 1990;64(6):734–6.CrossRef Leslie K, Crankshaw DP. Potency of propofol for loss of consciousness after a single dose. Br J Anaesth. 1990;64(6):734–6.CrossRef
16.
go back to reference Kwong TC. Free drug measurements: methodology and clinical significance. Clin Chim Acta. 1985;151:193–216.CrossRef Kwong TC. Free drug measurements: methodology and clinical significance. Clin Chim Acta. 1985;151:193–216.CrossRef
17.
go back to reference Dhillon S, Richens A. Valproic acid and diazepam interaction in vivo. Br J Clin Pharmacol. 1982;13:553–60.CrossRef Dhillon S, Richens A. Valproic acid and diazepam interaction in vivo. Br J Clin Pharmacol. 1982;13:553–60.CrossRef
18.
go back to reference Bhattacharya AA, Curry S, Franks NP. Binding of the general anesthetics propofol and halothane to human serum albumin: high resolution crystal structures. J Biol Chem. 2000;275:38731–8.CrossRef Bhattacharya AA, Curry S, Franks NP. Binding of the general anesthetics propofol and halothane to human serum albumin: high resolution crystal structures. J Biol Chem. 2000;275:38731–8.CrossRef
19.
go back to reference Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49:1239–76.CrossRef Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49:1239–76.CrossRef
20.
go back to reference American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry. 2002;159(4 Suppl):1–50. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry. 2002;159(4 Suppl):1–50.
21.
go back to reference Takizawa D, Takizawa E, Miyoshi S, Kawahara F, Hiraoka H. The increase in total and unbound propofol concentrations during accident hemorrhagic shock in patients undergoing liver transplantation. Anesth Analg. 2006;103:1339–40.CrossRef Takizawa D, Takizawa E, Miyoshi S, Kawahara F, Hiraoka H. The increase in total and unbound propofol concentrations during accident hemorrhagic shock in patients undergoing liver transplantation. Anesth Analg. 2006;103:1339–40.CrossRef
22.
go back to reference Hiraoka H, Yamamoto K, Okano N, Morita T, Goto F, Horiuchi R. Changes in drug plasma concentrations of an extensively bound and highly extracted drug, propofol, in response to altered plasma binding. Clin Pharmacol Ther. 2004;75:324–30.CrossRef Hiraoka H, Yamamoto K, Okano N, Morita T, Goto F, Horiuchi R. Changes in drug plasma concentrations of an extensively bound and highly extracted drug, propofol, in response to altered plasma binding. Clin Pharmacol Ther. 2004;75:324–30.CrossRef
23.
go back to reference Takizawa D, Sato E, Kurosaki D, Hiraoka H, Horiuchi R, Goto F. Pharmacodynamics of propofol during hemorrhagic shock. Anesthesiology. 2005;102:1068–9.CrossRef Takizawa D, Sato E, Kurosaki D, Hiraoka H, Horiuchi R, Goto F. Pharmacodynamics of propofol during hemorrhagic shock. Anesthesiology. 2005;102:1068–9.CrossRef
24.
go back to reference Mazoit JX, Samii K. Binding of propofol to blood components: implications for pharmacokinetics and for pharmacodynamics. Br J Clin Pharmacol. 1999;47(1):35–42.CrossRef Mazoit JX, Samii K. Binding of propofol to blood components: implications for pharmacokinetics and for pharmacodynamics. Br J Clin Pharmacol. 1999;47(1):35–42.CrossRef
25.
go back to reference Takizawa E, Hiraoka H, Takizawa D, Goto F. Changes in the effect of propofol in response to altered plasma protein binding during normothermic cardiopulmonary bypass. Br J Anaesth. 2006;96:179–85.CrossRef Takizawa E, Hiraoka H, Takizawa D, Goto F. Changes in the effect of propofol in response to altered plasma protein binding during normothermic cardiopulmonary bypass. Br J Anaesth. 2006;96:179–85.CrossRef
26.
go back to reference Kojima A, Bai JY, Ito Y, Ding WG, Kitagawa H, Matsuura H. Serum albumin attenuates the open-channel blocking effects of propofol on the human Kv1.5 channel. Eur J Pharmacol. 2016;783:117–26.CrossRef Kojima A, Bai JY, Ito Y, Ding WG, Kitagawa H, Matsuura H. Serum albumin attenuates the open-channel blocking effects of propofol on the human Kv1.5 channel. Eur J Pharmacol. 2016;783:117–26.CrossRef
27.
go back to reference Gomez MJ, Santos Buelga D, Alonso AC, Garcia MJ, Dominguez-Gil A. Effect of dose on the kinetic behaviour of valproic acid: modifications in plasma protein binding. Eur J Drug Metab Pharmacokinet. 1991;3:239–42. Gomez MJ, Santos Buelga D, Alonso AC, Garcia MJ, Dominguez-Gil A. Effect of dose on the kinetic behaviour of valproic acid: modifications in plasma protein binding. Eur J Drug Metab Pharmacokinet. 1991;3:239–42.
Metadata
Title
In vitro changes in the proportion of protein-unbound-free propofol induced by valproate
Authors
Minako Ishii-Maruhama
Hitoshi Higuchi
Mai Nakanou
Yuka Honda-Wakasugi
Akiko Yabuki-Kawase
Shigeru Maeda
Takuya Miyawaki
Publication date
01-10-2018
Publisher
Springer Japan
Published in
Journal of Anesthesia / Issue 5/2018
Print ISSN: 0913-8668
Electronic ISSN: 1438-8359
DOI
https://doi.org/10.1007/s00540-018-2540-6

Other articles of this Issue 5/2018

Journal of Anesthesia 5/2018 Go to the issue